Alignment with FDA on expedited development and design of Phase 2/3 registrational trial for BT8009 in metastatic bladder cancer, to be initiated in 1Q 2024
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BCYC:
- ‘The Stage Is Set for a Rally’: Canaccord Sees up to 290% Upside for These 3 Stocks
- Bicycle Therapeutics’ BT8009 for bladder cancer to participate in FDA program
- Pacira appoints four new independent directors to board of directors
- Bicycle Therapeutics upgraded to Buy from Neutral at B. Riley
- Bicycle Therapeutics announces expedited development plan for BT8009
